Pi-Cardia
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Seed | ||
€300k | Seed | ||
€10.0m | Late VC | ||
* | $20.0m Valuation: $48.7m | Late VC | |
* | N/A | $21.0m | Debt |
Total Funding | €28.5m |
Related Content
Recent News about Pi-Cardia
EditPi-Cardia is a medical device company specializing in non-implant based treatments for aortic valve repair. The company's core product, the Leaflex Performer, is designed to treat calcified aortic valves by creating scoring lines that separate calcium deposits, thereby increasing leaflet flexibility and improving valve hemodynamics. This unique mechanism aims to enhance the aortic valve area without the need for implants, offering a less invasive alternative to traditional valve replacement surgeries. Pi-Cardia primarily serves the cardiovascular healthcare market, targeting patients with aortic stenosis, a condition characterized by the narrowing of the aortic valve opening due to calcification. The business model revolves around the development, clinical testing, and eventual commercialization of its proprietary technology. Revenue is generated through the sale of the Leaflex Performer device to hospitals and healthcare providers. The company operates in a highly specialized segment of the medical device industry, focusing on innovative solutions that reduce procedure time, hospitalization duration, and overall healthcare costs.
Keywords: aortic valve repair, non-implant treatment, Leaflex Performer, calcification, leaflet flexibility, valve hemodynamics, cardiovascular healthcare, aortic stenosis, medical device, innovative solutions.